Research programme: neuroprotective therapies - Endo Pharmaceuticals

Drug Profile

Research programme: neuroprotective therapies - Endo Pharmaceuticals

Alternative Names: ADNF-9; AL-209; AL-309; AL-408; AL-508; SAL; SALLRSIPA

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allon Therapeutics
  • Developer Endo International
  • Class Nerve growth factors; Neuropeptides
  • Mechanism of Action Neuron stimulants; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • No development reported Alzheimer's disease; Eye disorders; Fetal alcohol syndrome; Neurodegenerative disorders; Peripheral nervous system diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Fetal-alcohol-syndrome in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top